Chiome Bioscience (TSE:4583) Change In Receivables: 円0.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4583 Chiome Bioscience Inc TSE:4583
51 GF Score
Price 円82.00
GF Value 円87.97
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Chiome Bioscience Change In Receivables?

Chiome Bioscience TSE:4583 +1.23% 51 Change In Receivables is 円0.0 Mil as of Jun. 2026. GuruFocus rates TSE:4583 with a GF Score™ of 51/100 and a GF Value™ of 円87.97 (Fairly Valued). The stock has 2 warning signs investors should review.

Chiome Bioscience's change in receivables for the quarter that ended in Jun. 2026 was 円0.0 Mil. It means Chiome Bioscience's Accounts Receivable stayed the same from Mar. 2026 to Jun. 2026 .

Chiome Bioscience's change in receivables for the fiscal year that ended in Dec. 2025 was 円-26.0 Mil. It means Chiome Bioscience's Accounts Receivable increased by 円26.0 Mil from Dec. 2024 to Dec. 2025 .

Chiome Bioscience's Accounts Receivable for the quarter that ended in Jun. 2026 was 円27.6 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Chiome Bioscience's Days Sales Outstanding for the three months ended in Jun. 2026 was 19.93.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Chiome Bioscience's liquidation value for the three months ended in Jun. 2026 was 円1,087.9 Mil.

Chiome Bioscience  (TSE:4583) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Chiome Bioscience's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=27.631/126.497*91
=19.93

2. In Ben Graham's calculation of liquidation value, Chiome Bioscience's accounts receivable are only considered to be worth 75% of book value:

Chiome Bioscience's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=1372.022-341.264+0.75 * 27.631+0.5 * 72.902
=1,087.9

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chiome Bioscience Change In Receivables Related Terms

Chiome Bioscience Change In Receivables Historical Data

* Premium members only.

The historical data trend for Chiome Bioscience's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chiome Bioscience Change In Receivables Chart

Chiome Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.25 -85.30 36.54 29.95 -26.03

Chiome Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4583
51GF Score
Chiome Bioscience Inc TSE:4583
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chiome Bioscience Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of 円0.0 Mil mean?
Chiome Bioscience (TSE:4583) has a Change In Receivables of 円0.0 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Chiome Bioscience and its competitors.
Is Chiome Bioscience's Change In Receivables too high?
Chiome Bioscience's current Change In Receivables is 円0.0 Mil. Overall, Chiome Bioscience has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's Change In Receivables compare to VRTX and REGN?
Chiome Bioscience's Change In Receivables of 円0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Chiome Bioscience and its competitors. Chiome Bioscience's current Change In Receivables is 円0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Fairly Valued. The stock's GF Value™ is 円87.97, compared to a current price of 円82.00 — trading 6.8% below its estimated fair value. The current Change In Receivables is 円0.0 Mil. Chiome Bioscience's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current Change In Receivables is 円0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chiome Bioscience (TSE:4583) Overvalued in 2026?

Based on GuruFocus' analysis, Chiome Bioscience stock appears to be undervalued. The current stock price of 円82.00 is trading 6.8% below its estimated GF Value™ of 円87.97. GuruFocus considers Chiome Bioscience to be Fairly Valued.

Key valuation signals for TSE:4583:

  • Change In Receivables: 円0.0 Mil
  • GF Value™: 円87.97 vs. price of 円82.00 (6.8% below fair value)
  • GF Score™: 51/100 with 2 warning signs

No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chiome Bioscience Business Description

Address 3-12-1 Honmachi, No. 6, Sumitomo Fudosan Nishi Shinjuku Building, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
51GF Score

Get the complete analysis for TSE:4583

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円82.00
Price
円87.97
GF Value